MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday

MiNK Therapeutics (NASDAQ:INKT) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect MiNK Therapeutics to post earnings of ($0.50) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

MiNK Therapeutics Stock Up 6.4 %

INKT stock opened at $8.49 on Friday. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00. The stock’s 50 day moving average is $8.94 and its two-hundred day moving average is $7.74. The company has a market capitalization of $33.65 million, a PE ratio of -2.18 and a beta of 0.16.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lifted their price objective on MiNK Therapeutics from $9.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.